Seek advice from HTA bodies for your clinical development program
Early dialogue/scientific advice from health technology assessment bodies (HTABs) is an opportunity to increase the probability of obtaining timely reimbursement at the target price in the appropriate patient population by generating the appropriate evidence. It is recommended to seek HTA advice prior to initiation of Phase III or pivotal trials and for real world evidence (RWE) generation.
The need for better alignment between evidence generation strategy and HTABs’ requirements calls for early engagement
Why should early advice from HTA bodies be considered?
Compared with regulatory agencies, HTA bodies have different mandates and methodologies and are focused on understanding the value and consequences of making a new treatment available, including how it will perform in the real world, its economics, and impact within the local organizational and social context. Early HTA engagement has become a vital part of market access strategy and planning.
Discuss with experts key aspects of early advice:
- Risks in seeking advice?
- Financial implications and resource needs?
- Which agencies to go to?
- Ready for real world evidence generation?
- Ready for early value proposition and early economic modelling plan?
- Impact on market access/reimbursement strategy?
Expert training on early HTA engagement
Meet with our experts to receive background information on early HTA advice and general considerations as well as information on stakeholders, processes, timing and requirements. We can discuss case studies and potential critical questions that might come up.
Be prepared for your next face-to-face or virtual meeting.
役員紹介
Elvira Müller, PhD, MPH VP HTA and Evidence Development
Roman Casciano, MEng SVP Evidence & Access
Matthew Brougham Sr. Expert Consultant
Elvira Müller, PhD, MPH VP HTA and Evidence Development
Roman Casciano, MEng SVP Evidence & Access
Matthew Brougham Sr. Expert Consultant
Elviraは、医療技術評価、償還戦略、EUnetHTAコラボレーションを通じた国内および複数HTAの早期対話において豊富な経験を持つHTAエンゲージメントのエキスパートです。
Roman Casciano は、サターラの Evidence and Access Group の Senior Vice President です。応用医療経済学者および市場アクセス戦略家として、ローマン氏は製品価値の実証に関連する国際市場アクセス、HEOR、およびリアルワールド・エビデンスにおいて、何百ものプロジェクトの関与を主導しており、支払者やHTA機関との公式および非公式の交流において深い経験を持っています。
He held senior public sector positions in Canada and New Zealand including 3 years as Vice President of CADTH and 5 years as Chief Executive of PHARMAC He is an expert in assessing value and value for money of health technologies.
Elviraは、医療技術評価、償還戦略、EUnetHTAコラボレーションを通じた国内および複数HTAの早期対話において豊富な経験を持つHTAエンゲージメントのエキスパートです。
Roman Casciano は、サターラの Evidence and Access Group の Senior Vice President です。応用医療経済学者および市場アクセス戦略家として、ローマン氏は製品価値の実証に関連する国際市場アクセス、HEOR、およびリアルワールド・エビデンスにおいて、何百ものプロジェクトの関与を主導しており、支払者やHTA機関との公式および非公式の交流において深い経験を持っています。
He held senior public sector positions in Canada and New Zealand including 3 years as Vice President of CADTH and 5 years as Chief Executive of PHARMAC He is an expert in assessing value and value for money of health technologies.
